Focused On-demand Library for N-formyl peptide receptor 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

FMLP-related receptor I; Formyl peptide receptor-like 1; HM63; Lipoxin A4 receptor; RFP

Alternative UPACC:

P25090; A8K3E2


N-formyl peptide receptor 2 (NPR2), also known as FMLP-related receptor I, Formyl peptide receptor-like 1, HM63, Lipoxin A4 receptor, and RFP, plays a pivotal role in immune response. It acts as a low affinity receptor for N-formyl-methionyl peptides, potent neutrophil chemotactic factors, triggering neutrophil activation via a G-protein that activates a phosphatidylinositol-calcium second messenger system. Furthermore, NPR2's interaction with the chemokine-like protein FAM19A5 stimulates macrophage chemotaxis and inhibits osteoclast differentiation, showcasing its anti-inflammatory potential by counteracting pro-inflammatory signals.

Therapeutic significance:

Understanding the role of N-formyl peptide receptor 2 could open doors to potential therapeutic strategies, particularly in modulating immune response and inflammation, offering insights into novel anti-inflammatory treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.